HK2 and neoplasm: In trastuzumab-resistant GC, metformin suppresses HK2-dependent glycolysis by inhibiting period circadian regulator 1 (PER1)-mediated circadian regulation of HK2, thereby restoring trastuzumab sensitivity and inhibiting tumor growth [91].